“Hardly worth the effort”? Medical journals’ policies and their editors’ and publishers’ views on trial registration and publication bias: quantitative and qualitative study by Elizabeth Wager and Peter Williams British Medical Journal. 2013 347:f5248 published on-line September 6, 2013 [full text on-line] Objectives To determine the proportion of medical journals requiring trial registration and to […]
In that video [a deal-breaker?…], Neal Parker of AbbVie, tells us that there are secrets in the Pharmaceutical Companies negotiations with regulators that might help the evil-doers in Bangladesh do a bio-equivalency study, clone his company’s product, and steal their business right out from under them. It might even be important to keep Adverse Effects […]
Who was that guy? The one in the video that seemed so outrageous [a deal-breaker?…, a window…]. And where was that meeting? What was it about? Neal Parker Section Head Legal – Biologics Strategic Development, Abbvie Neal Parker is a U.S. lawyer specializing in drug and biologic regulatory issues. He began his career more than […]
Unlocking Access to Clinical Trial Data What Are We Afraid of? HuffPost Tech UK by James Shannon GlaxoSmithKline’s Chief Medical Officer 3 September 2013 Today thousands of people all over the world will take part in clinical trials. Why do they volunteer, willingly sacrifice their time and in some cases experience discomfort and inconvenience? Of […]
After thinking about that last post, I tried to sit in Neal Parker’s of AbbVie’s shoes and feel his perspective. AbbVie sued when a rival petitioned for their clinical trial data. One of the tools of empathy is to try to think of a situation in your own life that matches the position of the […]
I apologize in advance for the length of this quote. This BMJ News article is posted on David Healy’s site as part of his post entitled Trade Wars we have known and loved: AbbVie v China. I’ve reposted it here because I found the PDF too blurry and I think it’s something everyone will want […]
Did you ever notice how quickly resolutions melt in the face of temptation? I had resolved that I wouldn’t lurk in wait for everything Dr. Lieberman writes so I can attack it as a way to protest the way his APA is running these days. I did pretty well until I got to the paragraphs […]
tar·get [tärgt] noun Something aimed or fired at. nov·el [nvl] adjective. Strikingly new, unusual, or different. I suppose a slang can arise almost anywhere. Until I started nosing around the tangles in psychiatric medications a few years back, I’d never heard these words used as I hear them now, certainly not in tandem – eg […]
[Note: Dates corrected] Back in January 2012, I wrote about Australian Depression/Sleep Guru, Ian Hickie, who had published an article in the August 2011 Lancet reviewing the studies of Agomelatine as an antidepressant positively [Novel melatonin-based therapies: potential advances in the treatment of major depression] to an international outcry of protest [of sound and fury…, […]
I can see that neither Jack Friday [Pharmagossip], our man on ChinaGate, nor the Chinese central authority took the weekend off to celebrate the US Labor Day: Reforms urged for pharma industry CHINADAILY USA By XU WEI 2013-09-04 Experts have called for reforms of public hospitals and more legislation on the pharmaceutical industry, after police […]